STEPHEN ANAYA: Open Payments
NPI 1992478507 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$241 in 12 payments from 9 companies in 2025. Trend: 2023 $465 · 2024 $169 · 2025 $241
Food & beverage: $241
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Novo Nordisk Inc | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Corcept Therapeutics | 1 | $29 |
| Amgen Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: ZENPEP, ENTRESTO, FARXIGA, Korlym, OTEZLA, REXULTI, ZEPBOUND, Auvelity.
Industry payments across TX — which companies pay providers there.
